PRTA Company Profile and Key Details

Q: Who are the executives of PRTA?

Ms. Carol D. KarpChief Regulatory OfficerDr. Hideki Garren M.D., Ph.D.Chief Medical OfficerMs. Karin L. Walker CPA, CPAChief Accounting Officer & ControllerMs. Jennifer ZibudaDirector of Investor Relations & CommunicationMr. Brandon S. SmithChief Operating OfficerMr. Michael J. MalecekChief Legal Officer & Company Sec.Dr. Gene G. Kinney Ph.D.Pres, Chief Executive Officer & DirectorDr. Wagner M. ZagoChief Scientific OfficerMs. Yvonne M. TchrakianCompany Sec.Mr. Tran B. Nguyen M.B.A.Chief Financial Officer & Chief Strategy Officer

NASDAQ : PRTA

Prothena

$8.83

-0.41-4.44%

At Close 4:00 PM

60.49

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Prothena Corporation plc (PRTA) stock declined over -4.44%, trading at $8.83 on NASDAQ, down from the previous close of $9.24. The stock opened at $9.14, fluctuating between $8.76 and $9.15 in the recent session.

Stock Snapshot

9.24

Prev. Close

462.28M

Market Cap

8.76

Day Low

-3.6

P/E Ratio

-2.45

EPS (TTM)

-2.55

Cash Flow per Share

9.14

Open

52.35M

Number of Shares

9.145

Day High

74.48%

Free Float in %

10.46

Book Value

758.93K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 13, 2026	9.17	9.19	8.76	8.83	781.72K
Jul 10, 2026	9.64	9.82	9.03	9.24	505.13K
Jul 09, 2026	9.83	10.02	9.55	9.64	482.22K
Jul 08, 2026	9.66	9.86	9.56	9.85	444.25K
Jul 07, 2026	9.62	9.78	9.33	9.68	520.54K
Jul 06, 2026	9.65	9.84	9.47	9.50	403.74K
Jul 02, 2026	9.61	10.15	9.57	9.69	462.88K
Jul 01, 2026	9.74	10.00	9.47	9.58	436.69K
Jun 30, 2026	9.96	10.04	9.75	9.79	339.63K
Jun 29, 2026	10.00	10.12	9.78	9.97	420.06K
Jun 26, 2026	9.32	10.09	9.28	10.02	1.91M
Jun 25, 2026	9.42	9.58	9.19	9.27	964.89K
Jun 24, 2026	9.57	9.87	9.26	9.40	477.86K
Jun 23, 2026	9.12	9.77	9.12	9.55	458.04K
Jun 22, 2026	8.90	9.27	8.89	9.15	612.35K
Jun 18, 2026	8.63	9.15	8.52	8.93	1.39M
Jun 17, 2026	8.39	8.72	8.39	8.49	542.97K
Jun 16, 2026	8.16	8.35	7.85	8.29	586.25K
Jun 15, 2026	8.69	8.77	7.93	8.15	622.61K
Jun 12, 2026	8.26	8.45	8.23	8.25	314.13K

Contact Details

Dublin, DU D02 VK60

Ireland

https://www.prothena.com 353 123 62500

About Company

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

Stock Peers

ARGX

-1.37-0.16%

argenx SE$876.25 REGN

-1.43-0.22%

Regeneron Pharmaceuticals, Inc.$663.09 UTHR

-11.49-2.10%

United Therapeutics Corporation$535.57 MDGL

-5.7-1.06%

Madrigal Pharmaceuticals, Inc.$531.00 VRTX

-5.14-1.06%

Vertex Pharmaceuticals Incorporated$480.25 KRYS

-2.37-0.65%

Krystal Biotech, Inc.$363.44 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-10.43-3.21%

Praxis Precision Medicines, Inc.$314.56 LGND

-6.99-2.21%

Ligand Pharmaceuticals Incorporated$309.25 ONC

5.26001+1.76%

BeOne Medicines AG$303.96

Company Overview

Prothena Corporation plc (NASDAQ:PRTA) closed at $8.83 USD, losing -$0.41 (-4.44%) from the previous close of $9.24. The stock is currently mid-range between its 52-week high and low $6.16 and $11.80. With a market capitalization of about $462.28 million, Prothena Corporation plc is classified as a small-cap and shows lower-than-market volatility (beta ~-0.31). Key stats such as the average daily volume over the past year has been around 534.56 thousand shares, in line with its 52-week average. Headquartered in Dublin, DU, Prothena Corporation plc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Gene G. Kinney, the company employs approximately 67 people and listed since December 20, 2012. Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.

Technical Performance

PRTA has shown mixed momentum, gaining 3.82% over the past week and -6.75% over the past quarter, though year-to-date performance is down -3.14%. Short-term trend indicators are mixed aligned (SMA20 -2.88%, SMA50 -6.26%, SMA200 2.32%). The stock’s 14-day RSI is 39.57 (weak momentum), while the ATR of 0.52 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -46.53% below its high and over 100.0% above its low. Average 10-day trading volume of 522.93 thousand shares is in line with the 3-month average of 540.30 thousand, indicating normal recent market interest.

Valuation Metrics

Prothena Corporation plc trades at a P/E ratio of -3.15, slightly below the S&P 500 average, with a price-to-sales ratio of 7.99 and a price-to-book ratio of 1.52 suggesting the stock is closer to book value. The P/FCF stands at -5.68, also above market averages.

Dividend & Fair Value

Prothena Corporation plc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.40. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Prothena Corporation plc generated EPS of -$4.53 over the past year. Five-year average earnings growth is -10.24%. The latest quarter delivered EPS of $0.60. The next quarter is forecast at -$0.35. Next year's EPS is expected at -$53.80. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 5 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $36.00 to $10.00. The high target offers 307.7% upside. The low target suggests 13.25% downside. The mean target is $18.00. This offers 103.85% upside. Prothena Corporation plc earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by -293.55%. The prior quarter beat by -2.22%. Over the last six quarters, Apple has recorded several small beats. These include 5.88% in February 20, 2025.

Shareholding & Insider Activity

Prothena Corporation plc has 53.83 million shares outstanding. The public float is 40.09 million shares, elevated short interest at 14.62% of float. This equals 4.18 million shares. The short ratio is 4.11 days. Institutional investors hold 114.54% of the float. Insiders own 20.76%. EcoR1 Capital, LLC holds 5.30 million shares, SCULLY WILLIAM P has 756.00 thousand shares and Kinney Gene G. has 12.79 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Prothena generated $91.37M in revenue, or $1.72 per share. Gross margin was 90.79%, operating margin -209.08%, and net profit margin -160.91%. Returns are negative, with ROA at -21.11% and ROE at -26.19%.
On valuation metrics, Prothena trades at a P/E of -3.15, P/S of 7.99 and P/B of 1.52. The current ratio is 10.43 and quick ratio is 10.43. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -50.95 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -10.63.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Prothena posted revenue of $91.37M, down slightly from $53.91M in the prior quarter. Gross profit was $82.96M (margin 90.79%). Operating income was - $191.04M (margin -209.1%). Net income was- $147.03M (EPS - $2.76).
The company ended the quarter with $620.18M in cash and short-term investments, a total debt of $11.84M, and net debt of - $608.35M. Total assets were $696.38M, with equity of $561.37M. Financials further reflected weakness, with operating cash flow of - $133.91M, free cash flow of - $136.72M, and capital expenditures of - $2.81M.

Price Forecast & Outlook

Our AI price prediction model suggests that Prothena Corporation plc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.95%, with price expected at $9.62 by July 27, 2026, within a range of $9.13 to $10.13 3-Month Outlook: Projected rise of 79.61%, reaching $15.86 by October 08, 2026, with a range of $15.11 to $16.64. 1-Year Outlook: Projected loss of -13.59%, with price at $7.63 by July 13, 2027, within a range of $0.00 to $3.86.

Key Takeaways

Prothena Corporation plc (NASDAQ:PRTA) shares are flat -3.14% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Prothena Corporation plc trading at a premium to the broader market with a P/E of -3.15. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $56.14, suggesting 535.79% upside. Our AI forecast model points to short-term strength (8.95% over two weeks), a medium-term rise (79.61% over three months), and a longer-term loss (-13.59% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Prothena Corporation plc (PRTA) stock price?

Prothena Corporation plc (NASDAQ: PRTA) stock price is $8.83 in the last trading session. During the trading session, PRTA stock reached the peak price of $9.15 while $8.76 was the lowest point it dropped to. The percentage change in PRTA stock occurred in the recent session was -4.44% while the dollar amount for the price change in PRTA stock was - $0.41.

PRTA's industry and sector of operation?

The NASDAQ listed PRTA is part of Biotechnology industry that operates in the broader Healthcare sector. Prothena Corporation plc designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PRTA?

Ms. Carol D. Karp
Chief Regulatory Officer
Dr. Hideki Garren M.D., Ph.D.
Chief Medical Officer
Ms. Karin L. Walker CPA, CPA
Chief Accounting Officer & Controller
Ms. Jennifer Zibuda
Director of Investor Relations & Communication
Mr. Brandon S. Smith
Chief Operating Officer
Mr. Michael J. Malecek
Chief Legal Officer & Company Sec.
Dr. Gene G. Kinney Ph.D.
Pres, Chief Executive Officer & Director
Dr. Wagner M. Zago
Chief Scientific Officer
Ms. Yvonne M. Tchrakian
Company Sec.
Mr. Tran B. Nguyen M.B.A.
Chief Financial Officer & Chief Strategy Officer

How PRTA did perform over past 52-week?

PRTA's closing price is 43.34% higher than its 52-week low of $6.16 where as its distance from 52-week high of $11.80 is -25.17%.

How many employees does PRTA have?

Number of PRTA employees currently stands at 67.

Link for PRTA official website?

Official Website of PRTA is: https://www.prothena.com

How do I contact PRTA?

PRTA could be contacted at phone 353 123 62500 and can also be accessed through its website. PRTA operates from 77 Sir John Rogersonâs Quay, Dublin, DU D02 VK60, Ireland.

How many shares of PRTA are traded daily?

PRTA stock volume for the day was 758.93K shares. The average number of PRTA shares traded daily for last 3 months was 534.56K.

What is the market cap of PRTA currently?

The market value of PRTA currently stands at $462.28M with its latest stock price at $8.83 and 52.35M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	67
Beta	-0.31
Sales or Revenue	$91.37M
5Y Sales Change%	70.122%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PRTA Company Profile and Key Details

Prothena

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways